Hormone Therapy and Castration Resistance of Prostate Cancer / edited by Yoichi Arai, Osamu Ogawa.

Format:

Book

Contributor:

Arai, Yōichi, editor.

Ogawa, Osamu, editor.

SpringerLink (Online service)

Language:

English

Subjects (All):

Medicine.

Oncology.

Urology.

Medicine & Public Health.

Local Subjects:

Medicine & Public Health.

Urology.

Oncology.

Physical Description:

1 online resource (VIII, 433 pages 65 illustrations, 34 illustrations in color)

Contained In:

Springer eBooks

Place of Publication:

Singapore : Springer Singapore : Imprint: Springer, 2018.

System Details:

text file PDF

Summary:

This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged. During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnic variation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.

Contents:

1. Introduction

2. Recent trends in hormone therapy for prostate cancer in Japan

3. Risk assessment among patients receiving primary ADT

4. Patient-derived xenografts for research on hormonal therapy of prostate cancer

5. Impact of GnRH antagonist and LHRH agonist on the gonadal axis

6. Controversies on complete androgen blockade

7. Adrenal androgen in prostate cancer

8. Intermittent ADT for prostate cancer

9. Pognostic significance of monitoring serum testosterone in primary ADT

10. Ethnic variation in clinical outcomes of primary ADT for prostate cancer

11. ADT in combination with radical prostatectomy

12. ADT in combination with radiation therapy

13. ADT as salvage therapy after definitive treatment

14. ADT for clinically localised prostate cancer

15. Complications of ADT

16. Hot flash

17. Oseteoporosis and fracture risk

18. Metaboplic change

19. Bone scan index as a biomarker of bone metastasis

20. Genetic polymorphism analysis in predicting prognosis of metastatic prostate cancer

21. Local therapy in combination with ADT for metastatic prostate cancer

22. Oxidative stress and CRPC

23. Alternative antiandrogen therapy for CRPC

24. Optimization of sequential AR targeted therapy for CRPC

25. Enzalutamide therapy for mCRPC in Japanese men

26. Abiraterone acetate therapy for mCRPC in Japanese men

27. Role of estramustine phosphate for CRPC

28. Steroid therapy for CRPC

29. MicroRNA analysis in prostate cancer

30. AR splicing variant in prostate cancer

31. Detection of CTC in CRPC

32. New biomarker for CRPC: Glycobiologic perspective

33. Bone-tageted treatment in CRPC management

34. Skeletal complications in CRPC patients

35. Urological complications in men dying from prostate cancer

36. Prediction of optimal docetaxel regimen for patients with mCRPC

37. Intermittent chemotherapy with decetaxel for mCRPC

38. Chemotherapy with cabazitaxel for ｍCRPC in Japanese men

39. New tageted approach to CRPC

40. Molecular basis of neuroendocrine prostate cancer

41. Gene therapy for prostate cancer

42. Immune therapy for CRPC

43. New approach to CRPC using inactivated virus

44. Patient-reported outcome in the management of CRPC.

Other Format:

Printed edition:

ISBN:

9789811070136

Access Restriction:

Restricted for use by site license.